This study included evaluation of five commercially available immunoassays for the detection of alprazolam and triazolam metabolites in urine following single oral doses of these drugs. The products investigated were the EMIT | d.a.u. TM assay, EMIT | II assay, Abbott TDx | (FPIA) assay, Bio Site TRIAGE TM device, and the Boehringer Mannheim/Microgenics CEDIA | assay for urinary benzodiazepines. Urine specimens were also analyzed quantitatively by gas chromatography-mass spectrometry. Percent cross-reactivity was assessed by analysis of drug free urine containing drug standards at concentrations ranging from 100 to 10,000 ng/mL. The drug standards analyzed were 0c-OHalprazolam, ~c-OH-triazolam, and 0c-OH-alprazolam glucuronide. The effect of lowering the screening cut-off value to 100 ng/mL, lowering the confirmation cut-off value to 50 and 25 ng/mL and the use of [3-glucuronidase hydrolysis prior to analysis was also studied. Lowering the screening cut-off value and using enzymatic hydrolysis prior to screening increased the positive detection rate for benzodiazepines with the EMIT d.a.u, assay and fluorescence polarization immunoassay (FPIA). The TRIAGE device gave the lowest percent cross-reactivity in the analysis of the drug standards and gave negative results in all urine specimens analyzed following ingestion of alprazolam and triazolam.
Introduction
Benzodiazepines are widely prescribed around the world because of their therapeutic use as anxiolytic agents, hypnotic properties, anticonvulsant activity, and muscle relaxant effect, as well as other uses. Alprazolam and triazolam were both developed by the Upjohn Company and are classified chemically as triazolobenzodiazepines. Alprazolam is commonly abused, and benzodiazepine analysis is often included in clinical and forensic drug screening programs. In a recent report on benzodiazepine abuse (1) , the observed abuse pattern of 10 benzodiazepines was studied. The highest observed abuse rate relative to extent of use of benzodiazepines in Canada was *Author to whom correspondence should be addressed.
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reported for alprazolam. In another recent study (2) , the behavioral, subjective, and reinforcing effects of immediate release and extended release alprazolam were compared in a double-blind crossover study to assess the effect of drug-release rate on objective measures of abuse liability. The authors demonstrated that the immediate release formulation of alprazolam had greater potential for abuse compared with the extended-release formulation.
Biotransformation of alprazolam and triazolam produces ~-OH-alprazolam and ~-OH-triazolam, respectively, which are then conjugated with glucuronic acid prior to excretion in the urine (3, 4) . Because cr glucuronide accounts for more than 65% of the triazolam metabolites excreted in urine, urine confirmation assays are directed toward this metabolite rather than the parent drug, which is excreted mostly unchanged (< 2%). Following oral doses of alprazolam, approximately 58% is excreted as cr glucuronide, and approximately 20% is excreted as unchanged drug. The relative proportions of the metabolites excreted varies with the time following dose. Identification of urine specimens for alprazolam and triazolam use is therefore directed toward analysis of these major metabolites following hydrolysis and not the unchanged drug.
Many different studies have been published (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) on the detection of benzodiazepines and metabolites in urine compared with confirmation procedures such as high-performance liquid chromatography (HPLC) and gas chromatography-mass spectrometry (GC-MS). A comprehensive evaluation of several different immmunoassays was reported by Fitzgerald (7) . Immunoassay studies specifically directed toward blood analysis have been published (15, 16) .
Because many hydroxylated benzodiazepine metabolites are conjugated prior to excretion, several investigators have evaluated the efficacy of enzymatic hydrolysis with [3-glucuronidase of urine specimens prior to immunoassay screening (17) (18) (19) (20) . For many immunoassays, such as EMIT d.a.u., EMIT II, and fluorescence polarization (FPIA), it was demonstrated that the positive rate for benzodiazepines increased following enzymatic hydrolysis. The need for enzymatic hydrolysis prior to analysis by the TRIAGE device was reported to be unnecessary because the monoclonal antibodies used in this device were prepared toward the conjugated metabolites (as hapten), not toward the unconjugated metabolites (5,6) used in other commercially available immunoassays.
The first objective of this study was to evaluate five immunoassays for urinary benzodiazepines by analysis of drug standards over a wide concentration range (100-10,000 ng/mL) and by analysis of urine specimens collected from individuals who received single oral doses of alprazolam or triazolam. Another objective was to study the effect of lowering the cut-off concentration to 100 ng/mL for the EMIT d.a.u., EMIT II, FPIA, and CEDIA immunoassays. The other objectives were to study the effect of enzymatic hydrolysis prior to screening urine specimens and to determine the optimal GC-MS cut-off value when the screening cut-off values were lowered to 100 ng/mL.
Materials and Methods
r and r were obtained from the Central Nervous System Diseases Research Office (Upjohn Co., Kalamazoo, MI). r glucuronide was purchased from Alltech-Applied Science Labs (State College, PA). Appropriate dilutions of concentrated standards in drug-free urine resulted in several urine standards ranging from 100-10,000 ng/mL for all three drug standards.
Urine specimens were collected from three volunteers who consumed single oral doses of alprazolam (0.5 rag) and, four weeks later, triazolam (0.25 rag). A total of 42 specimens were collected from the subjects within 24 h of alprazolam use, and 35 urine specimens were collected within 24 h of triazolam ingestion. Specimens were analyzed within 48 h of collection or stored frozen (5.0-mL aliquots) at -20~ until analyzed.
Screening analysis was performed by the EMIT II benzodiazepine assay (Syva Co., San Jose, CA) on a Hitachi 717 analyzer (Boehringer Mannheim Canada, Pointe Claire-Dorval, Quebec, Canada); by the EMIT d.a.u, assay on the EMIT ETS analyzer (Syva Co.); by the Abbott FPIA assay on an TDx-FLEX analyzer (Abbott Laboratories, Abbott Park, IL); by the Boehringer Mannheim Microgenics CEDIA assay (Concord, CA) on a Ciba Corning Express 550 analyzer (Richmond Hill, Ontario, Canada) according to a protocol provided by Boehringer Mannheim; and by the Bio Site TRIAGE device (Bio Site Diagnostics, San Diego, CA). Each immunoassay kit was used as specified by the manufacturer.
Calibrators were used as provided by the manufacturers for the 200 ng/mL cut-off and were diluted 1:1 with distilled water for the 100 ng/mL calibration. For the EMIT II assay, in-house oxazepam calibrators at 100 and 200 ng/mL were used as described previously (19) . For the TRIAGE assays, the device was used as specified by the manufacturer, and no attempts were made to modify calibration of the device.
Enzymatic hydrolysis was performed according to Meatherall (18) . Aliquots (1-mL) of urine were hydrolyzed at pH 4.5 with 50 IJL of Helix pomatia ~-glucuronidase (100,000 U/mL) (#G 7017; Sigma Chemical Co., St. Louis, MO). The mixture was incubated at approximately 56~ for 120 min. After cooling, the specimens were analyzed directly by immunoassay or by GC-MS.
All urine specimens were analyzed for benzodiazepines with and without enzymatic hydrolysis by all five immunoassays and by GC-MS. The GC-MS procedure for analysis of r alprazolam and a-OH-triazolam has been reported previously (21) . Cross-reactivity studies were performed on five occasions at concentrations ranging from 100 to 10,000 ng/mL.
Results
Cross reactivity for r ~-OH-alprazolam glucuronide, and r standards at concentrations ranging from 100 to 10,000 ng/mL are found in Figures 1A-C . For the EMIT d.a.u, assay, all three benzodiazepine metabolite standards gave a positive response between 100 and 200 ng/mL ( Figure 1A ). In the Abbott FPIA assay ( Figure 1B ), s-OHalprazolam was positive at approximately 200 ng/mL, whereas cr gtucuronide and r gave a positive response at approximately 500 ng/mL. The Microgenics CEDIA assay ( Figure 1C ) was most sensitive for alprazolam metabolites as shown by the positive results for the 100 ng/mL standards of both a-OH-aiprazolam and r glucuronide. The (z-OH-triazolam standard in the Microgenics CEDIA assay, however, was not positive until the concentration was approximately 1000 ng/mL. The Bio Site TRIAGE assay was positive for cr and a-OH-alprazolam glucuronide at 1000 ng/mL. The concentration of ~-OH-triazolam needed to give a positive response by the TRIAGE device was 5000 ng/mL. Cross-reactivity for the triazolobenzodiazepines with the EMIT II assay has been reported previously by Meatherall (19) .
The effect of lowering the immunoassay cut-off value to 100 ng/mL and including enzymatic hydrolysis prior to screening was studied for all assays except the TRIAGE device. Comparative results for the EMIT d.a.u, assay in the urine specimens from the subjects who consumed alprazolam are found in Fig Tables I and II . No comparative data for the TRIAGE device and GC-MS are provided because all urine specimens were negative for benzodiazepines (using TRIAGE) following use of alprazolam and triazolam.
Discussion
In the report by Buechler and co-workers (5), urine specimens found to be positive for various drugs in EMIT d.a.u, assays were also analyzed by the TRIAGE device and GC-MS. Compared with the EMIT d.a.u, assay, the TRIAGE assay was positive in 65 of 68 specimens and negative in 122 of 125. Agreement with GC-MS was seen for 187 of 193 urine specimens. Criteria for a positive GC-MS result were not specified. The TRIAGE device gave a positive response to various benzodiazepine standards added to drug-free urine at the following concentrations: cz-OH-alprazolam, 400 ng/mL and (z-OHalprazolarn glucuronide, 300 ng/mL. The reported concentrations (5) required to give a positive result are much lower than the findings of this current study. Immunoassay cut-off, 200 ng/mL; GC-MS cut-off, 25 ng/mL; no hydrolysis. u Immunoassay (ut-off, 200 n,g/mL; GC-MS cut-off, 25 ng/mL; hydrolysis. ' Immunoassay cut-off, 100 ng/mL; GC-MS cut-off, 50 ng/mL; no hydrolysis. ** Immunoassay cut-off, 100 ng/mL; GC-MS cut-off, 50 ng/mL; hydrolysis. tt Immunoassay cut-off, 100 ng/mL; GC-MS cut-off, 25 ng/mL; no hydrolysis. ** Immunoassay cut-off, 100 ng/mL; GC-MS cut-off, 25 ng/ml_; hydrolysis.
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Edinboro and Poklis (6) also evaluated the TRIAGE device for benzodiazepines. These authors stated that use of benzodiazepine antibodies directed toward the major glucuronide metabolites in the TRIAGE device would appear to provide Immunoassay cut-off, 200 ng/mL; GC-MS cut-off, 25 ng/mL; no hydrolysis. u Immunoassay cut-off, 200 ng/rnL; GC-MS cut-off, 25 ng/mL; hydrolysis. " Immunoassay cut-off, 100 ng/mL; GC-MS cut-off, 50 ng/mL; no hydrolysis. ** Immunoassay cut-off, 100 ng/mL; GC-MS cut-off, 50 ng/mL; hydrolysis. *t Immunoassay cut-off, 100 ng/mL; GC-MS cut-off, 25 ng/mL; no hydrolysis. ** Immunoassay cut-off, 100 ng/mL; GC-MS cut-off, 25 ng/mL; hydrolysis.
greater detection capability than the EMIT d.a.u, assay, which uses antibodies directed toward unconjugated benzodiazepines such as oxazepam. TRIAGE gave a positive screening result at 400, 300, 1000, and 750 ng/mL for a-OH-alprazolam, a-OHalprazolam glucuronide, a-OH-triazolam, and a-OH-triazolam glucuronide, respectively. The EMIT d.a.u, assay was stated as giving positive results at 60 and 100 ng/mL for a-OH-alprazolam and a-OH-triazolam, respectively. An overall agreement of 85% was reported between the EMIT d.a.u, assay and the TRIAGE device. There were 16 discordant specimen results for benzodiazepines in their study. In two specimens, the EMIT d.a.u, assay and GC-MS were both positive for a-OH-triazolam but negative by the TRIAGE device. In an additional eight specimens, the EMIT d.a.u, assay was positive and the GC-MS was positive for 1-3 benzodiazepine metabolites. The TRIAGE device was negative for benzodiazepines in these eight specimens. The TRIAGE device, however, was felt to be more sensitive than the EMIT d.a.u, assay for detecting lorazepam and high concentrations of temazepam. The authors also stated that a combination of TRIAGE and EMIT d.a.u, analysis would provide for a more comprehensive approach for screening of benzodiazepines and metabolites in urine than the use of either the TRIAGE or the EMIT d.a.u, assay. The low cross-reactivity to triazolam metabolites by TRIAGE (6) is consistent with the results of the current study.
Fitzgerald (7) compared six immunoassays, EMIT d.a.u., EMIT II, Roche Abuscreen On-Line, Abbott TDx (FPIA), Diagnostic Products Corp (DPC), and Bio Site TRIAGE, for benzodiazepine metabolites in urine with confirmation by negative chemical ionization (NCI) GC-MS. In 100 clinical specimens suspected of containing a benzodiazepine, 91 were positive for a benzodiazepine as determined by NCI GC-MS. The GC-MS assay was quantitative at 50 ng/mL for most benzodiazepine metabolites and quantitative down to 10 ng/mL for lorazepam and oxazepam. In this study, the EMIT d.a.u, assay gave 64 true positives, 7 false negatives, 29 true negatives, and no false positives. The false negatives contained either lorazepam or 7-aminoclonazepam. The TRIAGE device produced 72 true positives, 25 true negatives, 3 false negatives, and no false positives for this group. The Abbott FPIA assay produced 58 true positives, 33 true negatives, 9 false negatives, and no false positives. For the EMIT II, there were 67 true positives, 25 true negatives, 8 false negatives, and no false positives. In this group of 100 specimens, one specimen contained a-OH-alprazolam, and one specimen contained a-OH-triazolam. The authors concluded that all the kits evaluated were acceptable for screening for benzodiazepines. The DPC RIA and TRIAGE were able to detect lorazepam, unlike the four other assays. Unfortunately, the number of specimens containing triazolobenzodiazepines in this study was too small (N = 2) to compare the various immunoassays for alprazolam or triazolam.
Koch (8) reported a study comparing Bio Site TRIAGE, EMIT d.a.u., and Abbott FPIA for benzodiazepines with GC-MS. Precision of the TRIAGE device was assessed by analysis of a-OHalprazolam glucuronide standards from 150-450 ng/mL. At concentrations greater than or equal to 330 ng/mL, all analyses were positive for benzodiazepines. In the analysis of 319 specimens, there were 157 true positives, 149 true negatives, 4 false negatives, and 9 false positives by the TRIAGE device. By comparison, in 326 specimens analyzed by the EMIT d.a.u. assay, there were 154 true positives, 99 true negatives, 14 false negatives, and 59 false positives. For the Abbott FPIA assay, there were 127 true positives, 153 true negatives, 41 false positives, and 5 false positives. The definition of false positive by these authors was "any specimen with GC-MS quantitation less than 300 ng/mL after a positive immunoassay screening result". It has been shown by several authors (6, 7, 9, 20) that some benzodiazepine assays can easily detect many benzodiazepines and metabolites at much lower concentrations than their immunoassay cut-off values of 200 or 300 ng/mL. Therefore, to be considered a true false positive, the authors would have to establish that there were no benzodiazepine metabolites (by GC-MS analysis) at a much lower cut-off value than the screening cut-off (50-100 ng/mL or lower) and include as many benzodiazepines and metabolites as possible in their confirmation assay. Following alprazolam and triazolam use, several metabolites are excreted in the urine, including the parent drug and a-OH-alprazolam glucuronide (9, 10) . Unfortunately, the authors did not identify which benzodiazepine metabolites were detected or quantitated in the administratively defined "false positives" and "false negatives" for the three immunoassays. The actual number of "true" false positives by the EMIT d.a.u, and Abbott FPIA assays was probably much lower than stated by these authors because of the sensitivity of those two assays. For certain drugs of abuse, it is appropriate to have the same cut-off for screening and confirmation. In most laboratories, drugs with many metabolites, such as cannabinoids, have much lower confirmatory cut-off values than the screening assay. Benzodiazepines, such as triazolam and alprazolam, that have many metabolites known to cross-react in immunoassays should also have lower confirmatory cut-off values than the screening assay.
Asselborn and Wennig (11) evaluated the TRIAGE device in comparison with Abbott FPIA for the analysis of 299 urine specimens. Compared with FPIA, they found 90 true positives, 146 true negatives, 56 false negatives, and 7 false positives by TRIAGE. Confirmatory analysis of the discrepant specimens was not discussed. K~iferstein (12) also compared the TRIAGE device and the EMIT d.a.u, assay followed by HPLC analysis of the benzophenones formed following acid hydrolysis. In 45 specimens (88% of total), there was agreement between the EMIT d.a.u, assay and the TRIAGE results. Three TRIAGE positive results were not confirmed by HPLC, and two TRIAGE negative specimens were found to contain either flunitrazepam or bromazepam. The unconfirmed TRIAGE results may not have been true "false positives" because certain benzodiazepines do not form a benzophenone with acid treatment (14) .
In the cross-reactivity tables provided by Bio Site for the TRIAGE device (22) , the lowest concentrations of benzodiazepines giving positive results were as follows: 600 ng/mL for a-OH-alprazolam, 750 ng/mL for a-OH-alprazolam glucuronide, and 1000 ng/mL for a-OH-triazolam. These threshold values are higher than the values reported in 1992 in a Bio Site study (5) , but lower than the cross-reactivity resuits found in this study. Possible factors contributing to these variations are lot to lot variation in TRIAGE devices and changes in the mixtures of antibodies used in the device.
Beck (17) reported improved detection of oxazepam by Abbott FPIA by enzymatic hydrolysis prior to screening. He evaluated hydrolysis of urine specimens containing oxazepam conjugates with [~-glucuronidase from E. coli by modifying incubation times, enzymatic activity, and temperature of incubation. Meatherall (18) evaluated hydrolysis conditions for urine specimens containing glucuronide conjugates of temazepam, oxazepam, lorazepam, c~-OH-alprazolam, 2-hydroxyethylflurazepam, and N-desalkyl-3-hydroxyflurazepam. Several [~-glucuronidase formulations, various enzyme activities, hydrolysis temperatures, and incubation times were studied. Optimal recovery of hydrolyzed drug occurred when 1 mL of urine buffered to a pH of 4.5 was incubated with 5000 U of Helbcpornatia 13-glucuronidase at 56~ for 2 h. This hydrolysis procedure was evaluated for screening of several benzodiazepines using the Abbott FPIA and EMIT II reagents for urine specimens obtained following oral dosing with diazepam, oxazepam, temazepam, lorazepam, alprazolam, flurazepam and chlordiazepoxide in humans. Meatherall (19) reported that hydrolysis is necessary to optimize the detection rate for oxazepam, temazepam, and lorazepam when using the Abbott FPIA or the EMIT II assay. For oxazepam, a 200 ng/mL cut-off resulted in an 80% false-negative rate for both immunoassays. After hydrolysis, both methods gave 100% positive results. Improved detection of temazepam was identical to oxazepam (before and after hydrolysis). The effect of hydrolysis, however, was not as significant for alprazolam, especially for analysis by the Abbott FPIA assay.
Simonsson (20) also studied the effects of [3-glucuronidase on benzodiazepine detection. He evaluated urine specimens collected from five patients being treated with oxazepam and also studied drug-free urine. The objective of the study was to determine the effect of deconjugation on the sensitivity and specificity of the Abbott FPIA assay for benzodiazepines. Analysis of 35 urine specimens by FPIA without hydroIysis gave 22 positive results, whereas 33 of 35 were positive with enzymatic hydrolysis prior to screening. These authors also studied the effect of ff-glucuronidase on the specificity of the immunoassay. The enzyme treatment did not affect the calibrator reactivity, recovery of unconjugated oxazepam or alter the immunoreactivity of 14 urine specimens obtained from drug-free subjects. This study was initiated partly because of concerns expressed by a representative of Abbott Laboratories about modifying specimens used for testing with a procedure not validated by the manufacturer (23) .
An extensive multi-center evaluation was reported (13) that compared the performance of the CEDIA immunoassay for urine benzodiazepines with the performance of the EMIT II assay and GC-MS. At the single site evaluating the CEDIA benzodiazepine assay (200 ng/mL cut-off), there was 99% agreement with the EMIT II assay and only one discordant result (a specimen containing nordiazepam). Overall, using a 200 ng/mL cut-off, CEDIA sensitivity versus GC-MS was 96% with 14 false positives compared with 96% sensitivity (EMIT II) with 3 false positives. The CEDIA false positives contained the following: sertraline (6 specimens), embramine (3 specimens), phenelzine (1 specimen), oxazepam (1 specimen), tc-OH-alprazolam near the cut-off (1 specimen), and both nordiazepam and oxazepam near the cut-off (1 specimen). The definition of false positive was "when a screening result was positive (200 ng/mL cut-off) and the GC-MS concentration was below the confirmation cut-off of 200 ng/mL". The three false-positive specimens containing benzodiazepines below the confirmation cut-offwere defined as false positives administratively, but were probably not false positives analytically. The GC-MS assays were targeted to measure only certain benzodiazepine metabolites, not all the metabolites known to cross-react with the antibodies used in the CEDIA formulation. As discussed with the EMIT d.a.u, and Abbott FPIA assays (7, 9, 10) , confirmatory cut-off concentrations for triazolobenzodiazepines should be at lower values than the screening assays to prevent classifying specimens as false positives because the screening assays cross-react with several metabolites and the confirmatory assay measures only one metabolite.
In Tables I and II , the positive rates for alprazolam and triazolam varied with the screening cut-off (100 or 200 ng/mL), enzymatic hydrolysis, and the GC-MS cut-off (25 or 50 ng/mL). In the EMIT d.a.u, assay, the highest number of true positives was found (alprazolam) when the screening cut-off was 200 ng/mL, hydrolysis was performed, and the GC-MS cut-offwas 25 ng/mL. For triazolam by the EMIT d.a.u, assay, the number of true positives was highest with a screening cut-off of 100 ng/mL without hydrolysis. The FPIA assay was most sensitive to alprazolam when the screening cut-offwas 100 ng/mL after hydrolysis and the GC-MS cut-off was 25 ng/mL. For triazolam by FPIA, triazolam was only detected whenever the screening cut-off was 100 ng/mL following hydrolysis. The greatest increase in true positives (alprazolam) for the EMIT II assay was by lowering the cut-off to 100 ng/mL and using a GC-MS cut-off of 25 ng/mL.
For triazolam, the EMIT ll assay gave the highest number of true positives with a screening cut-offof 100 ng/mL. Use ofhydrolysis and a lower GC-MS cut-off did not increase the true positive rate for triazolam by the EMIT II assay. The highest true positive rate for the CEDIA assay (alprazoIam) was using a 200 ng/mL cut-off without hydrolysis and the GC-MS cut-off at 25 ng/mL. The CEDIA assay was not sensitive to triazolam use even when the screening cut-off was lowered to 100 ng/mL. In Figure 1C , cr gave a positive CEDIA response at approximately 1000 ng/mL. Overall, the highest true-positive rate for alprazolam was with the EMIT II assay with the screening cut-off at 100 ng/mL (with or without hydrolysis) and GC-MS cut-off at 25 ng/mL. For triazolam, the highest true-positive rate was for the EMIT d.a.u, assay with a 100 ng/mL cut-off and no hydrolysis.
Huang and colleagues (15, 16) have reported the cross-reactivity of several benzodiazepines and corresponding metabolites in whole blood by several different commercially available immunoassays. Their studies showed that radioimmunoassays (RIA) can detect most benzodiazepines and metabolites at lower concentrations than EMIT and FPIA assays. Some benzodiazepines, such as c~-OH-alprazolam, had better cross-reactivity at 70 ng/mL with EMIT d.a.u., EMIT tox, FPIA urine, and FPIA serum assays than with radioimmunoassay (RIA) (DPC). They concluded that it is difficult to determine that any one assay is better or more sensitive than another assay for the detection of all benzodiazepines.
Evaluation of the cross-reactivity of benzodiazepines and their metabolites in various immunoassays does vary with the lot number of reagent used. For example, the cross-reactivity of (~-OH-triazolam in the EMIT d.a.u, assay was determined in the same laboratory on two occasions prior to this study (9, 14) . The EMIT d.a.u, assay has been shown to provide improved cross-reactivity toward this triazolam metabolite since first evaluated in 1987.
Conclusion
In summary, it was found that evaluation of the reliability of various immunoassays for the triazolobenzodiazepines is dependent on the cut-off value used for the screening assay and the confirmation assay. The conclusions of several previous studies were based on the assumption that the most appropriate GC-MS cut-off was the same value as the screening cut-off. In our view, the confirmation cut-off for these benzodiazepines should be much lower than the screening cut-off in order to ascertain the actual number of true positives and false positives. The specific confirmation cut-off used is dependent on the instrumentation available in each laboratory. It is our recommendation, however, that screening assays for alprazolam and triazolam have a cut-off of 100 ng/mL and a confirmatory cut-off of 25 ng/mL. The results of this study confirm previous reports (17) (18) (19) (20) demonstrating the value of including enzymatic hydrolysis prior to screening. It would be very helpful to laboratories testing for triazolobenzodiazepines when the major diagnostic companies provide enzymatic hydrolysis as an integral part of their product. The current assay with antibodies directed toward the glucuronide metabolites (TRIAGE) is unable to detect alprazolam and triazolam after single doses based on the poor cross-reactivity to alprazolam and triazolam metabolite standards and the negative results found for the urine specimens collected following ingestion of triazolam and alprazolam.
